BioPharma Resources

Drug Trial Radar · NCT02879305

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents

Last checked: Nov 19, 2026Latest source record: Dec 3, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,964 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,964

Actual

Start

Sep 28, 2016

Primary completion

Nov 9, 2020

Study completion Nov 9, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this multi-center event-driven study in participants with anemia associated with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.

Conditions

  • Anaemia
  • Aspergillosis, Allergic Bronchopulmonary

Interventions

  • DaprodustatDrug

    Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.

  • rhEPODrug

    The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.

  • PlaceboDrug

    Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

  • Iron therapyDrug

    Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority AnalysisTime frame: Up to 3.9 person-years for CV follow-up time period
  2. Mean Change From Baseline in Hemoglobin (Hgb) Levels During Evaluation Period (Week 28 to Week 52)Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)

Locations

462 sites in 35 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Huntsville, Alabama

  • GSK Investigational Site

    Pine Bluff, Arkansas

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Bakersfield, California

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Cerritos, California

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    El Centro, California

  • GSK Investigational Site

    Escondido, California

  • GSK Investigational Site

    Fairfield, California

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Glendale, California

  • GSK Investigational Site

    Granada Hills, California

  • GSK Investigational Site

    Hacienda Heights, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    La Palma, California

  • GSK Investigational Site

    Lakewood, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Lynwood, California

  • GSK Investigational Site

    Montebello, California

  • GSK Investigational Site

    Monterey Park, California

  • GSK Investigational Site

    Moreno Valley, California

  • GSK Investigational Site

    Norco, California

  • GSK Investigational Site

    Northridge, California

  • GSK Investigational Site

    Ontario, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Luis Obispo, California

  • GSK Investigational Site

    Santa Clarita, California

  • GSK Investigational Site

    Simi Valley, California

  • GSK Investigational Site

    Tarzana, California

  • GSK Investigational Site

    Whittier, California

  • GSK Investigational Site

    Whittier, California

Showing 40 of 462 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.